Impacts of the American Joint Committee on Cancer (AJCC) 8th edition tumor, node, metastasis (TNM) staging system on outcomes of differentiated thyroid cancer in Thai patients
| Autor: | Veekij Veerasomboonsin, Yotsapon Thewjitcharoen, Krittadhee Karndumri, Rajata Rajatanavin, Ekgaluck Wanothayaroj, Soontaree Nakasatien, Siriwan Butadej, Waralee Chatchomchuan, Sirinate Krittiyawong, Sriurai Porramatikul, Thep Himathongkam, Auchai Kanchanapituk |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Staging TNM staging system 8th edition Papillary thyroid cancer 03 medical and health sciences 0302 clinical medicine Internal medicine Medicine Stage (cooking) lcsh:Social sciences (General) Tumor node metastasis lcsh:Science (General) Thyroid cancer Multidisciplinary AJCC business.industry Thyroid Cancer medicine.disease Differentiated thyroid cancer 030104 developmental biology medicine.anatomical_structure Cohort lcsh:H1-99 business 030217 neurology & neurosurgery lcsh:Q1-390 |
| Zdroj: | Heliyon, Vol 7, Iss 3, Pp e06624-(2021) |
| ISSN: | 2405-8440 |
| Popis: | Background In 2018, the American Joint Committee on Cancer (AJCC) 8th edition (AJCC8) was introduced to replace the previous version (AJCC7) due to superiority of AJCC8 over AJCC7 for better prediction of survival from thyroid cancer. Aim To compare AJCC staging systems with the American Thyroid Association (ATA) risk classification for the prediction of 5-year disease-free survival (DFS), and 5-year disease-specific survival (DSS) in Thai patients. Methods We retrospectively reviewed all patients with histopathologic diagnosis of DTC who were treated at Theptarin Hospital, Bangkok, Thailand from 1987 to 2019. Results The study cohort included 262 differentiated thyroid cancer (DTC) patients (papillary thyroid cancer 89.7% with a median time of follow-up 7.8 years). The number (%) of patients within each stage group by AJCC7 and AJCC8 respectively are as follows: Stage I: 173 (66.0%) vs. 232 (88.5%), Stage II: 33 (12.6%) vs. 24 (9.2%), Stage III: 36 (13.7%) vs. 2 (0.8%), Stage IV: 20 (7.7%) vs. 4 (1.5%). The ATA high risk group was found in 24.3% of AJCC7 Stage I compared with 23.7% of AJCC8 Stage I. The 5-year DFS rates in patients classified as stages I, II, III, and IV by AJCC8 were 87.9%, 45.8%, 0% and 25%, respectively. The 5-year DSS rates in patients classified as stages I, II, III and IV by AJCC8 were 98.7%, 100%, 100% and 0%, respectively. AJCC8 was more predictive of DFS rate than AJCC7. Conclusions Our study is in accord with previous studies that AJCC8 downstage a significant percentage of patients with DTC and correlated with better prognostic validity. However, even a person at low risk for mortality can be at high risk for recurrence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|